NASDAQ:GLUE | Free Cash Flow | Monte Rosa Therapeutics, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2020-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$37.37M$1.87M-$39.24M
2025-12-31-$43.01M$767,000.00-$43.78M
2025-03-31-$45.49M$1.59M-$47.08M-100.41%
2024-12-31$128.92M$183,000.00$128.74M958.09%
2024-03-31-$38.17M$1.38M-$39.55M
2023-12-31$29.63M$1.69M$27.95M
2023-03-31-$23.41M$9.18M-$32.59M
2022-12-31-$23.96M$7.27M-$31.23M
2022-03-31-$27.4M$1.69M-$29.09M
2021-12-31-$14.17M$3.06M-$17.23M
2021-03-31-$13.82M$2.22M-$16.03M
2020-12-31-$8.57M$1.19M-$9.76M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$22.8M$4.7M-$27.5M
2024-12-31$42M$3.99M$38.01M
2023-12-31-$43.8M$19.04M-$62.84M
2022-12-31-$92.47M$12.91M-$105.38M
2021-12-31-$59.36M$9.73M-$69.1M
2020-12-31-$23.05M$3.39M-$26.44M